Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy

Diabetes and Metabolism

Volumn 30, Issue 4, 2004, Pages 311-318

  Ambroisine, M L ^a   Milliez, P ^a   Nehme, J ^a   Pasquier, A L ^a   De Angelis, N ^a   Mansier, P ^a   Swynghedauw, B ^a   Delcayre, C ^a,b  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Aldosterone; Cardiac hormones; Diabetic nephropathy; Heart failure; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HORMONE RECEPTOR BLOCKING AGENT; POTASSIUM; SCLEROPROTEIN; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ALDOSTERONE ESCAPE; ANTIHYPERTENSIVE ACTIVITY; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CELL TYPE; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; END ORGAN DAMAGE; GYNECOMASTIA; HEART FAILURE; HEART MUSCLE FIBROSIS; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HYPERTENSION; IMPOTENCE; INFLAMMATION; KIDNEY COLLECTING TUBULE; LONG TERM CARE; MENSTRUATION DISORDER; NON EPITHELIAL TISSUE; NONHUMAN; OXIDATIVE STRESS; POTASSIUM BLOOD LEVEL; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TISSUE; TISSUE INJURY; TISSUE NECROSIS;

EID: 4644278371     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70122-2     Document Type: Review

References (53)

1. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med, 1999, 341, 753-5.
2. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol, 2001, 280, F181-92.
3. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation, 1997, 95, 1471-8.
4. Brilla C, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol, 1993, 125, 563-75.
5. Robert V, Nguyen VT, Cheav SL, Mouas C, Swynghedauw B, Delcayre C. Increased cardiac types I and III collagen mRNAs in Aldo-salt hypertension. Hypertension, 1994, 24, 30-6.
6. Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res, 1997, 35, 138-47.
7. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt treated rats. Effects of Eplerenone. Circulation, 2002, 106, 2848-53.
8. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther, 1995, 9, 145-9.
9. Lijnen PM, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol, 1982, 49, 1561-3.
10. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy, Hypertension, 2003, 41, 64-8.
11. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol, 1988, 60, 820-5.
12. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Biochem, 2004, in press.
13. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens, 2002, 15, 709-16.
14. Pitt B, Zannad F, Remme WJ, et al., for the Randomized ALdactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med, 1999, 341, 709-17.
15. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of Excessive Extracellulat Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES). Circulation, 2000, 102, 2700-6.
16. Ramires FJA, Sun Y, Weber KT. Myocardial fibrosis associated with Aldo or angiotensin II administration: attenuation by calcium channel blockade. J Mol Cell Cardiol, 1998, 30, 475-83.
17. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol, 2001, 37, 1800-7.
18. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation, 2000, 101, 594-7.
19. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-LeFt Ventricular Hypertrophy Study. Circulation, 2003, 108, 1831-8.
20. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol, 2003, 42, 1674-6.
21. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: twelve percent incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol, 1993, 20, 296-8.
22. Halimi JM, Mimram A. Albuminuria in untreated patients with primari aldosteronism or essential hypertension. J Hypertens, 1995, 13, 1801-2.
23. Nishimura M, Uzu T, Fuji T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis, 1999, 33, 261-6.
24. White WB, Duprez D, St Hillaire R, et al. Effects of selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension, 2003, 41, 1021-6.
25. Sato A, Takane H, Saruta T. High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients. Hypertens Res, 2001, 24, 99-104.
26. Grandi AM, Imperiale D, Santillo R, et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension, 2002, 40, 647-52.
27. Pitt B, Remme W, Zannad F, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial infarction. N Engl J Med, 2003, 348, 1309-21.
28. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol, 2003, 14, 2395-401.
29. Shiigai T, Shichiri M. Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis, 2001, 37, 477-83.
30. Epstein M, Buckalew V, Martinez F, et al. Antiproteinuric efficacy of eplerenone, enalapril and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens, 2002, 15, 24A (abstract).
31. Robert V, Heymes C, Silvestre J, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension, 1999, 33, 981-6.
32. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol, 1985, 63, 1522-7.
33. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier Jr CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension, 1998, 31, 451-8.
34. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest, 1996, 98, 1063-8.
35. Rocha R, Stier CT Jr, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal injury. Endocrinology, 2000, 141, 3871-8.
36. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol, 2002, 283, H1802-10.
37. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart. Am J Pathol, 2002, 161, 1773-81.
38. Nicoletti A, Michel JB. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res, 1999, 41, 532-43.
39. Virais A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension, 2002, 40, 504-10.
40. Schafer A, Fraccarollo D, Hildemann SK, Tas P, Ertl G, Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res, 2003, 58, 655-62.
41. Young MJ, Moussa L, Dilley R, Funder JW. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology, 2003, 144, 1121-5.
42. Gerling IC, Sun Y, Ahokas RA, et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol, 2003, 285, H813-21.
43. Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological Regulations. J Biol Chem, 1998, 273, 4883-91.
44. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular Aldo. Biosynthesis and a link to angiotensin II induced hypertrophy of vascular smooth muscle cells. J Biol Chem, 1994, 269, 24316-20.
45. Casal AJ, Silvestre JS, Delcayre C, Capponi AM. Expression and modulation of the Steroidogenic Acute Regulatory (StAR) protein mRNA in rat cardiocytes and after myocardial infarction. Endocrinology, 2003, 144, 1861-8.
46. Silvestre J, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation, 1999, 99, 2694-701.
47. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol, 2002, 34, 1577-84.
48. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation, 2001, 103, 72-7.
49. White PC. Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab, 2003, 88, 2376-83.
50. Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy. Circulation, 2004, 109, 1284-91.
51. Funder JW. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu Rev Med, 1997, 48, 231-40.
52. Qin W, Rudolph AE, Bond BR, et al. Transgenic Model of Aldosterone-Driven Cardiac Hypertrophy and Heart Failure. Circ Res, 2003, 93, 69-76.
53. Beggah AT, Escoubet B, Puttini S, et al. Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc Natl Acad Sci USA, 2002, 99, 7160-5.